Table 3 Assay-specific performance estimates.

Data source	Parameter	Abbott	DiaSorin	Roche
Validation experiment only	Sensitivity	0.939 (0.797–0.993)^a	0.852 (0.767–0.914)^b	0.939 (0.797–0.993)^a
Validation experiment only	Specificity	1.00 (0.934–1.00)^c	1.00 (0.832–1.000)_d	0.976 (0.874–0.999)^e
Validation experiment & serosurvey results	Sensitivity	0.969 (0.926–0.994)	0.856 (0.801–0.904)	0.968 (0.924–0.994)
Validation experiment & serosurvey results	Specificity	0.997 (0.994–0.999)	0.982 (0.976–0.987)	0.997 (0.994–0.999)
Validation experiment & serosurvey results	PPV	0.906 (0.855–0.951)	0.627 (0.539–0.720)	0.916 (0.866–0.963)
Validation experiment & serosurvey results	NPV	0.999 (0.999–1.000)	0.995 (0.992–0.998)	0.999 (0.999–0.999)

Mean and 95% CI of the sensitivity and specificity obtained from the validation experiments only (VEO) and from the combined validation experiments and serosurvey results reported in Table 2. The sample sizes are given in the footnote. PPV positive predictive value; NPV negative predictive value. The 95% CrI around the PPV and NPV have been estimated by bootstrapping.
^a33 SARS-CoV-2 PCR positive tested ≥ 30 days post symptom onset, of which 31 seropositive.
^b101 SARS-CoV-2 PCR positive tested ≥ 30 days post symptom onset, of which 86 seropositive.
^c54 SARS-CoV-2 PCR negative tested, of which 54 seronegative.
^d20 SARS-CoV-2 PCR negative tested, of which 20 seronegative.
^e42 SARS-CoV-2 PCR negative tested, of which 41 seronegative.

Quick links

Search